Botanical Traceability and Adulteration: A Buyer’s Guide
Botanical adulteration is not limited to obvious contamination. It can include substitution with another species, use of the wrong plant part, dilution with low-cost material, undeclared carriers, synthetic marker addition or a genuine herb processed in a way that no longer matches the agreed specification.
For buyers, the most effective defence is a connected control system. Documentation, supplier qualification, botanical identity and chemistry should support one another from the source material to the released extract batch.
Traceability connects the claimed botanical to the commercial batch and its test evidence.
1. Know the main failure modes
Risk | Example | Useful control
Risk: Species substitution • Example: A cheaper related plant replaces the specified species • Useful control: Botanical authentication and fit-for-purpose fingerprinting
Risk: Plant-part substitution • Example: Leaf or stem replaces root, fruit or flower • Useful control: Farm records, morphology where possible and chemical profile
Risk: Dilution • Example: Excess carrier, starch or exhausted material • Useful control: Full composition, microscopy, mass balance and marker profile
Risk: Fortification • Example: Isolated or synthetic marker added to reach assay • Useful control: Multi-marker profile and orthogonal testing
Risk: Document mismatch • Example: COA and label describe different grades • Useful control: Batch-level reconciliation and specification control
2. Traceability starts before extraction
The chain should record botanical name, plant part, cultivation or collection area, harvest period, drying method, lot number and initial supplier. For high-risk plants, an authenticated voucher or reference sample can strengthen future investigations.
3. One marker is rarely enough
A single assay may confirm that a compound is present, but not that the claimed botanical created it. Related species can share markers, and isolated compounds can be added. Stronger programs combine identity techniques such as macro- or microscopy, TLC or HPTLC, chromatographic fingerprints, targeted assays and other methods selected for the processed form.
4. DNA has strengths and limitations
DNA methods can be valuable for raw or lightly processed material, but extraction, heat and purification may degrade or remove DNA. A negative or inconclusive result in a concentrated extract does not automatically prove substitution. Method selection must match the material.
5. Reconcile the commercial documents
The purchase order, specification, COA, manufacturing record, invoice and shipping documents should agree on species, plant part, extract ratio, marker, carrier, origin and batch number. Inconsistencies can reveal that the quoted grade and shipped grade are not the same.
6. Use a risk-based testing plan
Testing intensity should reflect ingredient value, known adulteration history, supply-chain length, geographic risk, process complexity and intended dose. New suppliers and unusual price movements justify additional scrutiny. Established suppliers still require periodic verification and change notification.
7. Retain samples and investigate deviations
Keep representative pre-shipment, received and released samples where practical. If colour, odour, density, solubility or fingerprint changes unexpectedly, place the lot on hold and compare it with approved reference batches before relying on a repeat assay alone.
Buyer checklist
Define species, author, plant part and preparation.
Map the supply chain and processing sites.
Identify likely adulterants and failure modes.
Select methods that can discriminate them.
Reconcile documents and composition.
Verify new suppliers and periodically retest established supply.
Record deviations, investigations and corrective action.
Related Herbify guides
How Herbify can help
Herbify supports Australian and New Zealand product developers, contract manufacturers and brands with botanical extract sourcing, specification matching, samples, technical documentation and custom-format discussions.
Regulatory note: ingredient suitability, permitted claims and labelling depend on the final product category, dose, formulation and market. This article provides general commercial information and is not medical, legal or regulatory advice.
Comments